Jennifer Ford

Michigan

Managing Editor at Retinal Physician

Senior Managing Editor at Glaucoma Physician

Featured in: Favicon

retinalphysician.com Favicon

glaucomaphysician.net Favicon

forbes.com Favicon

wiley.com

bmj.com

biomedcentral.com Favicon

eyecarebusiness.com Favicon

onlinelibrary.wiley.com Favicon

oem.bmj.com Favicon

implementationscience.biomedcentral.com

Articles

April

3 weeks ago | eyecarebusiness.com | Kerri Ann DeCindis |Veronica Daub |Sheena Taff |Jennifer Ford

TrendSpotting: Sustainability in Sight To mark Earth Month, EB shares a collection of recent sustainability efforts across the optical industry. Optometric Business Tracker EB + GPN offer a fresh focus on industry data—exploring a specific aspect of the optometric practice with each issue. Here, GPN shares insights into polycarbonate lenses as a key lens opportunity for patients.
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS

Jul 19, 2024 | retinalphysician.com | Jennifer Ford

Today at the 2024 meeting of the American Society of Retina Specialists in Stockholm, Michael Singer, MD, presented late-breaking data on Nanoscope Therapeutics’s multicharacteristic opsin (MCO) optogenetics gene therapy platform (Figure 1). The 100-week top-line results were from the phase 2b/3 RESTORE randomized sham-controlled clinical trial of MCO-010 in retinitis pigmentosa.
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS

Jul 18, 2024 | retinalphysician.com | Jennifer Ford

Today at the 2024 meeting of the American Society of Retina Specialists in Stockholm, Dilsher S. Dhoot, MD, presented a late-breaking interim analysis from the HELIOS study of Axpaxli (OTK-TKI; Ocular Therapeutix), a sustained-release axitinib implant. The phase 1 HELIOS study is evaluating Axpaxli vs sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema.
TEASE-3 Study Data on Oral Therapy for Stargardt Disease Presented at ASRS

Jul 18, 2024 | retinalphysician.com | Jennifer Ford

Today at the 2024 meeting of the American Society of Retina Specialists in Stockholm, Michael Gorin, MD, PhD, presented late-breaking data on the TEASE-3 trial of oral gildeuretinol acetate (ALK-001; Alkeus Pharmaceutical) for Stargardt disease. The TEASE trials consist of 4 independent clinical studies of gildeuretinol in Stargardt disease, TEASE-1, TEASE-2, TEASE-3, and TEASE-4. TEASE-3 is an open-label study assessing gildeuretinol in early-stage Stargardt patients.
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting

Jul 17, 2024 | retinalphysician.com | Jennifer Ford

At the 2024 meeting of the American Society of Retina Specialists in Stockholm, Sweden, Raj Maturi, MD, presented late-breaking data on the dose-expansion cohort of the PRISM trial of 4D-150 (4DMT).
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS

Jul 17, 2024 | retinalphysician.com | Jennifer Ford

At the 2024 meeting of the American Society of Retina Specialists in Stockholm, Veeral S. Sheth, MD, MBA, FASRS, FACS, presented late-breaking data on supplemental injection in the DAVIO 2 trial of Duravyu (EYP-1901; EyePoint Pharmaceuticals). DAVIO 2 is a phase 2 randomized, prospective clinical trial comparing a single injection of Duravyu at 2 doses vs aflibercept (Eylea; Regeneron) in patients receiving a mean 10 anti-VEGF injections per year for wet AMD.
Uveitis Corner: Spotlight on Young Uveitis Specialists

May 1, 2024 | retinalphysician.com | Jennifer Ford

The Young Uveitis Specialists (YUS) group is a subsection of the American Uveitis Society (AUS). They are a professional group of early career uveitis specialists and specialists in training. Here, Retinal Physician speaks with founding members Arthi Venkat, MD; Edmund Tsui, MD; Kareem Moussa, MD; Jessica Shantha, MD; and Eric Crowell, MD, about the organization and its goals. Retinal Physician: Dr. Venkat, could you describe how YUS was formed?
Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni

Apr 23, 2024 | retinalphysician.com | Jennifer Ford

The ophthalmic community was shocked by the sudden loss of Professor Ramin Tadayoni, MD, PhD. Prof. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend. His vision for advancing research and advocating for funding changes resonated deeply with colleagues and peers. Prof.
Study Published of RadiusXR VR Perimetry Platform

Mar 28, 2024 | glaucomaphysician.net | Jennifer Ford

RadiusXR has announced the publication of results from its NOVA study in the journal Translational Vision Science and Technology. The study aimed to compare estimated sensitivities of SITA-Standard to the RATA-Standard algorithm of the Radius head-mounted virtual reality perimeter (VRP) and to measure concordance in glaucoma staging.
ViaLase Completes Enrollment for Pivotal Trial of Laser for POAG

Dec 1, 2023 | glaucomaphysician.net | Jennifer Ford

ViaLase announced that the company has completed enrollment for VIA-002, a pivotal trial of the ViaLase Laser to treat adult patients with primary open-angle glaucoma (POAG). The ViaLase Laser combines femtosecond laser technology and micron-level image guidance to deliver a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy, or FLigHT.